Cyted continues rapid expansion and shares new growth programme

• Cyted has piloted a novel managed digital pathology model for over 5,000 tests with NHS and private hospitals, with the aim to scale in 2022.
• New partnerships with private healthcare providers have been established to build managed pathways and virtualise pathology operations.
• Cyted has supported the national roll-out of over 3,500 of its early oesophageal cancer diagnostic tests to date into NHS services across England and Scotland with European pilots being underway.
• Over the next six months, the company headcount will double to further develop and support the uptake of its technologies, and laboratory operations will be moved to larger premises in Huntingdon, UK.

CAMBRIDGE, UK, 7th September 2021: Cyted has shared its plans for further growth as the company is set to double its headcount during the next six months.

Recent expansion has seen Cyted reaffirm its commitment to pioneering diagnostic platforms through new partnerships, to build new managed pathways and virtualise pathology operations. The programme is focused on streamlining services during the COVID-19 era and easing pressures on the health system as it recovers from the impact of the pandemic.

This growth also follows the delivery of over 3,500 diagnostic tests to NHS services across England and Scotland in Cyted’s first managed pathway, known as the Cytosponge test, and the pilot of a novel managed digital pathology model.

Through the earlier and faster diagnosis of disease, the implementation of managed pathways in primary and secondary care helps to conserve pathologists’ time, save costs, reduce wait times and improve patient outcomes. Through diagnosis of Barrett’s oesophagus, a condition which increases the likelihood of oesophageal cancer, Cyted has already helped over 3,500 patients enter the care pathway earlier; halting the progression of cancer and reducing pressure on the system.

Over the coming months, Cyted will continue to support the NHS in the roll-out of its technology, digital diagnostic infrastructure and services to enable the earlier and faster detection of a range of diseases.

Since starting operations in 2020, Cyted has evolved from a team of three scientists and clinicians from the University of Cambridge. To support the implementation of its technology and platforms, Cyted will double its headcount from the current team of 40 over the next six months. Cyted will move its laboratory operations to a new building in Huntingdon in late 2021 to accommodate this growth.

Marcel Gehrung, Co-founder & Chief Executive Officer at Cyted,comments:

“At Cyted, we are committed to building a world where disease is prevented rather than treated. We recognise that cancer services in the UK are under extreme pressure, something which has been compounded by the COVID-19 pandemic. Our game-changing technology aims to offer solutions that relieve some of this pressure through essential earlier and faster detection of disease.

“To continue to deliver on this, we must ensure we have the best minds as part of our team. We are excited to be doubling our dedicated team of pioneers and specialists to facilitate the delivery of our existing services and to develop new solutions that improve outcomes for patients.”

About Cyted

Cyted is building a world where disease is prevented rather than treated. We are committed to enabling the earlier and faster detection of disease, providing game-changing technology that is at the cutting-edge of what machine learning and automatic can do. Our products and services combine artificial intelligence technology and digital diagnostic infrastructure with next generation biomarkers.

With significant expertise in pathology, we are streamlining diagnostic and clinical workflows. Our pioneering, fully managed, end-to-end diagnostic platform has the power to save pathologists time, give clinicians quicker access to answers and enable access to better outcomes for all. For more information, please visit www.cyted.ai.

About The Cytosponge Test

The Cytosponge involves sampling cells from the surface of the oesophagus using the Cytosponge cell collection device by Medtronic, consisting of a mesh sphere on a string inside a gelatine capsule. The capsule is swallowed by the patient and the gelatine capsule dissolves in the stomach allowing the sponge to expand. The sponge is then withdrawn from the stomach, sampling cells from the surface of the oesophagus. The cells and biomarkers associated with Barrett’s Oesophagus are then analysed using the Cyted pathology platform.

Cyted Press Office

Hanover Communications
E-mail :cyted@hanovercomms.com